Diagnostics
-
CAP urges HHS to revoke lab developed test rule, citing Trump order
The pathologists group wants the regulation terminated in light of an executive order from President Trump that calls for federal agencies to “alleviate unnecessary regulatory burdens.”
By Nick Paul Taylor • Feb. 26, 2025 -
Thermo Fisher to buy Solventum’s purification and filtration unit for $4.1B
Wall Street applauded the deal, sending shares of Solventum, the 3M spinoff, up 10% on Tuesday.
By Susan Kelly • Feb. 25, 2025 -
Explore the Trendline➔
Sitthiphong via Getty ImagesTrendlineMedical device industry continues to turn to AI
While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.
By MedTech Dive staff -
Quest to buy Fresenius Medical Care kidney testing assets
The acquisition will add dialysis-related water testing to Quest’s portfolio and position the company to perform the tests and other end-stage kidney disease services for Fresenius Medical Care.
By Nick Paul Taylor • Feb. 25, 2025 -
Guardant accuses Natera of poaching employees, stealing trade secrets
The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position in the early cancer test industry.”
By Nick Paul Taylor • Updated 20 hours ago -
GE Healthcare invests $138M to expand contrast media production at Ireland site
The new facility will enable production of 25 million more patient doses per year by the end of 2027.
By Nick Paul Taylor • Feb. 4, 2025 -
23andMe considers sale as cash runs low
The genetic testing company ended last year with $79.4 million and told investors it will need to raise money to fund its operations and financial commitments.
By Nick Paul Taylor • Jan. 30, 2025 -
Neko Health raises $260M to expand body scan service, fund R&D
The company uses various medical devices to noninvasively check moles, the heart and more.
By Nick Paul Taylor • Jan. 28, 2025 -
Illumina, Nvidia team to use AI in foundation models
Nvidia’s partnership with the gene sequencing company is one of several healthcare collaborations revealed Monday by the computing giant.
By Susan Kelly • Jan. 13, 2025 -
EU medtech regulations reducing options for patients, companies say
Stakeholders branded the MDR and IVDR rules “unreasonably complicated,” “terrible for EU patients and doctors” and “a mess.”
By Nick Paul Taylor • Jan. 13, 2025 -
Top 10 medtech deals of 2024
Multibillion-dollar buyouts returned last year, led by Johnson & Johnson’s $13.1 billion acquisition of Shockwave Medical.
By Nick Paul Taylor • Jan. 2, 2025 -
Labcorp closes takeover of Ballad Health outreach laboratory services
Labcorp continued its streak of hospital lab purchases with a deal that will expand its testing capabilities to communities in Tennessee, Virginia, North Carolina and Kentucky.
By Nick Paul Taylor • Dec. 12, 2024 -
Guardant awarded nearly $293M in false ad trial against Natera
Natera allegedly made “false and misleading statements” to convince people to use its Signatera cancer test rather than Guardant’s rival product Reveal.
By Nick Paul Taylor • Dec. 2, 2024 -
Medtronic wins VA contract to install AI-powered endoscopy units
The three-year contract expands Medtronic’s work with the VA to cover the installation of almost 100 more GI Genius endoscopy modules at U.S. centers.
By Nick Paul Taylor • Nov. 26, 2024 -
Labcorp hires Julia Wang as CFO
Wang will replace Glenn Eisenberg, who is retiring after 10 years in the role. Evercore analysts called Eisenberg a Labcorp “institution.”
By Susan Kelly • Nov. 20, 2024 -
Retrieved from GE Healthcare on November 14, 2024
GE Healthcare’s head-only MRI scanner cleared by the FDA
The system is designed to shorten scan times, which may be better for people who struggle to stay still or have claustrophobia, and to detect more subtle abnormalities.
By Nick Paul Taylor • Nov. 14, 2024 -
23andMe to lay off more than 200 employees amid business struggles
The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.”
By Ricky Zipp • Nov. 13, 2024 -
Advamed CEO congratulates Trump, stresses need for public policy support
Donald Trump’s election victory comes weeks after the FDA named a new leader for the medical device center and as the agency’s contentious LDT final rule is challenged in court.
By Ricky Zipp • Nov. 11, 2024 -
Exact Sciences’ forecast cut shocks analysts
The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer screening company’s stock on Wednesday.
By Nick Paul Taylor • Nov. 8, 2024 -
Tempus AI to buy genetic testing company for $600M
CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing business.
By Elise Reuter • Nov. 6, 2024 -
Advamed asks CMS to cover extra imaging of dense breast tissue
Many patients with dense breast tissue currently have to pay out of pocket or forgo potentially life-saving additional testing, Advamed said in a letter.
By Nick Paul Taylor • Nov. 6, 2024 -
European Parliament calls for proposals to reform MDR and IVDR by end of Q1
Parliament asked the European Commission to publish acts that address the “most pressing challenges and bottlenecks” of the regulations and propose the “systematic revision” of the legislation.
By Nick Paul Taylor • Oct. 24, 2024 -
The Medtech Conference
Medtech Conference recap: New CDRH leader details approach; AI and LDTs in focus
Catch up on our recent coverage of Advamed’s The Medtech Conference.
By Elise Reuter • Oct. 23, 2024 -
GE Healthcare opens AI Innovation Lab to grow new projects
The AI Innovation Lab is designed to accelerate early concept artificial intelligence projects including tools to predict the recurrence of cancer and automate image interpretation.
By Nick Paul Taylor • Oct. 22, 2024 -
Deep Dive
5 steps to navigate the FDA’s new lab developed test rule
Laboratories face a series of upcoming deadlines to comply with stricter FDA oversight of in-house tests. Here are five strategies labs can take to be ready.
By Susan Kelly • Oct. 21, 2024 -
FDA prioritizes guidance on lab developed tests in 2025 plan
The Center for Devices and Radiological Health intends to develop final guidance on its enforcement discretion policy regarding special controls for LDTs, among other topics.
By Nick Paul Taylor • Oct. 18, 2024